Production and Characterization of a Novel OX40 Ligand for Clinical Use
Annual rept. 15 Jul 2008-15 Jul 2009
PROVIDENCE HEALTH SYSTEMS-OREGON PORTLAND
Pagination or Media Count:
The goals of the first yearphase of the DOD funded research, PC073499, have been accomplished. We produced two human versions of the OX40 ligandtrimerIg protein. The two protein constructs have different human trimer domains TRAF2 and Matrillin-4, which confer differing folding patterns within the two-dimension structure of the protein. Both the TRAF2 and Matrilin-4 trimer domain constructs appear to have as good if not better in vitro bioactivity when compared to a mouse anti-human OX40 Ab that is currently in a clinical trial for cancer patient treatment. We have produced enough purified material to test the in vivo activity of these proteins and have planned a pilot study involving injection of these new human OX40 agonists in non-human primates. Upon completion of this project we will have important preclinical information that should allow for FDA approval of a fully human OX40 agonist to be tested in a clinical trial.
- Medicine and Medical Research
- Organic Chemistry